Anastrozole: a medicine to treat and prevent breast cancer

Patients receiving ARIMIDEX had a lower incidence of hotflashes, vaginal bleeding, vaginal discharge, endometrial cancer, venousthromboembolic events and ischemic cerebrovascular events compared withpatients receiving tamoxifen. ARIMIDEX is indicated for thefirst-line treatment of postmenopausal Letrozole pharmacy price women with hormone receptor-positive orhormone receptor unknown locally advanced or metastatic breast cancer. ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. The dose of Arimidex is one 1 mg tablet taken once a day.

Other uses for this medicine

Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of serious side effects will increase. Read the Patient Information Leaflet if available from your pharmacist before you start taking anastrozole and each time you get a refill.

How much does Anastrozole cost without insurance?

Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval. Anastrozole is an aromatase inhibitor that is used as adjuvant therapy in the treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women. It is also used to treat advanced breast cancer that has grown or spread after tamoxifen treatment. Anastrozole is not effective in treating breast cancer who have not gone through menopause. All patients received calcium and vitamin D supplementation.

• This is only a brief summary of general information about this medicine.
• It reduces the risk of breast cancer by 53% after 7 years of follow-up, and 50% after 10.9 years of follow-up.
• Ask your doctor for ways to prevent these effects or make them less severe.
• In Trial 0004, 81% of patients wereER-positive, 13% were ER-unknown, and 6% were ER-negative.

Description for Arimidex

ARIMIDEX does not possess direct progestogenic, androgenic, or estrogenic activity in animals, but does perturb the circulatinglevels of progesterone, androgens, and estrogens. In multiple daily dosing trials with 3, 5, and 10 mg, theselectivity of anastrozole was assessed by examining effects on corticosteroid synthesis. For all doses, anastrozole did not affect cortisol or aldosteronesecretion at baseline or in response to ACTH. No glucocorticoid ormineralocorticoid replacement therapy is necessary with anastrozole. The effect of ARIMIDEX in premenopausal women with earlyor advanced breast cancer has not been studied. Because aromatization ofadrenal androgens is not a significant source of estradiol in premenopausalwomen, ARIMIDEX would not be expected to lower estradiol levels inpremenopausal women.

Dialysis may be helpful because ARIMIDEX is not highly protein bound.General supportive care, including frequent monitoring of vital signs and closeobservation of the patient, is indicated. ARIMIDEX may cause fetal harm when administered to apregnant woman and offers no clinical benefit to premenopausal women with breast cancer. ARIMIDEX is contraindicated in women who are or may becomepregnant. In animal studies, anastrozole caused pregnancy failure, increasedpregnancy loss, and signs of delayed fetal development. There are no studies ofARIMIDEX use in pregnant women. If ARIMIDEX is used during pregnancy, or if thepatient becomes pregnant while receiving this drug, the patient should be apprisedof the potential hazard to the fetus and potential risk for pregnancy loss.